Published in Mol Biol Cell on October 26, 2005
Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A (2008) 2.25
E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res (2007) 1.70
ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. J Am Soc Nephrol (2011) 1.61
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat (2008) 1.42
Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A (2008) 1.39
ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol (2009) 1.28
The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell (2006) 1.23
ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia (2008) 1.20
HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.20
Cell death or survival promoted by alternative isoforms of ErbB4. Mol Biol Cell (2010) 1.07
The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Mol Endocrinol (2007) 1.05
ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med (2013) 1.05
Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes. Cancer Res (2011) 1.01
The fibroblast-derived paracrine factor neuregulin-1 has a novel role in regulating the constitutive color and melanocyte function in human skin. J Cell Sci (2010) 1.00
ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis. Mol Biol Cell (2007) 1.00
gamma-Secretase: a multifaceted regulator of angiogenesis. J Cell Mol Med (2008) 0.99
Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells. FASEB J (2009) 0.96
A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle (2010) 0.95
Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res (2010) 0.94
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Breast Cancer Res (2011) 0.92
Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo. J Biol Chem (2012) 0.92
Proteolytic processing of ErbB4 in breast cancer. PLoS One (2012) 0.90
Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol Res (2006) 0.90
ErbB-4 and TNF-alpha converting enzyme localization to membrane microdomains. Biochem Biophys Res Commun (2006) 0.90
Neuregulin3 alters cell fate in the epidermis and mammary gland. BMC Dev Biol (2007) 0.90
Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling. J Biol Chem (2012) 0.89
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget (2014) 0.89
Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein. J Biol Chem (2012) 0.87
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res (2009) 0.86
HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4. Cancer Res (2007) 0.85
ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. Carcinogenesis (2015) 0.84
Activating ERBB4 mutations in non-small cell lung cancer. Oncogene (2015) 0.84
Upregulation of epidermal growth factor receptor 4 in oral leukoplakia. Int J Oral Sci (2013) 0.83
The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients. BMC Cancer (2013) 0.81
EGF and TGF-β1 Effects on Thyroid Function. J Thyroid Res (2011) 0.80
Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells. Mol Cancer Res (2014) 0.79
Ectodomain shedding of interleukin-2 receptor beta and generation of an intracellular functional fragment. J Biol Chem (2010) 0.79
Developmental pruning of excitatory synaptic inputs to parvalbumin interneurons in monkey prefrontal cortex. Proc Natl Acad Sci U S A (2017) 0.78
Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis. Breast Cancer Res (2014) 0.78
Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor. BMC Cell Biol (2009) 0.77
The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056. Growth Factors (2007) 0.77
Hypoxia-inducible factor-1α induces ErbB4 signaling in the differentiating mammary gland. J Biol Chem (2014) 0.77
ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation. Cell Death Dis (2017) 0.75
Cleavage of Signal Regulatory Protein α (SIRPα) Enhances Inflammatory Signaling. J Biol Chem (2015) 0.75
Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE. J Biol Chem (2016) 0.75
Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis. Oncotarget (2016) 0.75
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst (1973) 10.64
The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer (2004) 5.47
gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 4.90
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol (2003) 4.05
WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem (2003) 3.65
Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell (1992) 2.62
The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol (2004) 2.41
Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. Science (1988) 2.29
Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem (2000) 2.11
Phosphatidylinositol 3-kinase activity is required at a postendocytic step in platelet-derived growth factor receptor trafficking. J Biol Chem (1995) 2.06
A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem (1997) 1.99
Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer (2003) 1.95
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res (1997) 1.91
Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem (2001) 1.87
Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol (2001) 1.80
Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res (2000) 1.63
The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem (1996) 1.58
ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res (2002) 1.58
A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem (2000) 1.55
Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene (1999) 1.46
An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem (1996) 1.43
Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med (2000) 1.39
Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. J Biol Chem (1996) 1.36
Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res (2004) 1.35
Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am (1997) 1.28
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res (1999) 1.25
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res (2003) 1.23
TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. J Cell Biol (1996) 1.22
Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism. J Cell Biol (1997) 1.20
Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res (2003) 1.19
Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem (2003) 1.17
Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res (1999) 1.10
Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol (2003) 1.09
c-erbB-4/HER4: friend or foe? J Pathol (2003) 1.00
Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol (2001) 1.00
BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells. Biochem Biophys Res Commun (2001) 0.98
Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ (2002) 0.98
Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells. Int J Cancer (2000) 0.93
Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res (1996) 0.93
ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta Oncol (2004) 0.88
ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. Int J Cancer (1999) 0.86
Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. Cancer Res (1998) 0.83
Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell (2009) 14.40
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A (2003) 4.69
Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA (2004) 4.01
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol (2009) 3.63
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res (2010) 3.54
GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell (2008) 3.44
Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell (2012) 2.61
Web-based virtual microscopy in teaching and standardizing Gleason grading. Hum Pathol (2005) 2.56
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther (2004) 2.47
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res (2005) 2.39
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res (2003) 2.15
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest (2002) 2.06
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia (2005) 1.98
Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell (2012) 1.95
Dynamic, long-term in vivo imaging of tumor-stroma interactions in mouse models of breast cancer using spinning-disk confocal microscopy. Cold Spring Harb Protoc (2011) 1.95
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol (2003) 1.87
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res (2006) 1.85
CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res (2009) 1.81
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
The application of JPEG2000 in virtual microscopy. J Digit Imaging (2007) 1.76
A web-based system for individualised survival estimation in breast cancer. BMJ (2003) 1.70
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol (2004) 1.70
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther (2007) 1.70
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res (2003) 1.65
Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC Cardiovasc Imaging (2011) 1.63
ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. J Am Soc Nephrol (2011) 1.61
System-wide analysis reveals a complex network of tumor-fibroblast interactions involved in tumorigenicity. PLoS Genet (2013) 1.59
ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res (2002) 1.58
A metabolic prosurvival role for PML in breast cancer. J Clin Invest (2012) 1.57
Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.57
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res (2007) 1.54
Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res (2002) 1.54
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res (2002) 1.53
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer (2002) 1.51
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res (2006) 1.51
Monitoring of vital signs for long-term survival of mice under anesthesia. Cold Spring Harb Protoc (2011) 1.50
Coevolution of cancer and stromal cellular responses. Cancer Cell (2005) 1.50
Preparation of mice for long-term intravital imaging of the mammary gland. Cold Spring Harb Protoc (2011) 1.50
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) (2006) 1.43
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43
Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol (2003) 1.43
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol. J Digit Imaging (2009) 1.39
Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci U S A (2008) 1.39
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res (2011) 1.39
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol (2005) 1.38
Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J (2003) 1.38
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol (2004) 1.37
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech (2010) 1.35
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett (2010) 1.35
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer (2008) 1.31
ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry. Histopathology (2012) 1.30
ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol Cell Biol (2009) 1.28
Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res (2003) 1.27
Function of ERBB4 is determined by alternative splicing. Cell Cycle (2011) 1.26
The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol Biol Cell (2006) 1.23
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res (2003) 1.23
Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res (2014) 1.21
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol (2012) 1.20
Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J Biol Chem (2004) 1.20
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett (2011) 1.18
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat (2007) 1.14
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res (2003) 1.14
Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem (2008) 1.11
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier. Lab Invest (2003) 1.10
Endothelial cell-matrix interactions. Microsc Res Tech (2003) 1.09
Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia (2009) 1.09
Web-based virtual microscopy for parasitology: a novel tool for education and quality assurance. PLoS Negl Trop Dis (2008) 1.08
Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study. J Pathol (2004) 1.08
Cell death or survival promoted by alternative isoforms of ErbB4. Mol Biol Cell (2010) 1.07
Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol (2011) 1.07
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett (2005) 1.06
Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep (2010) 1.05